Drug intelligence / Profile preview

visepegenatide

Development stage: Phase 3
Lead developer: PegBio
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

Visepegenatide (PB-119) is a long-acting, once-weekly, subcutaneous glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is a PEGylated form of exenatide designed to improve glycemic control in patients with type 2 diabetes mellitus by enhancing beta-cell function and reducing insulin resistance. Unlike some other GLP-1 RAs, visepegenatide does not require dose titration. Clinical studies have demonstrated its efficacy in lowering HbA1c and improving multiple markers of glucose metabolism. The drug has been developed primarily for the treatment of type 2 diabetes mellitus and is also being investigated for obesity[2][3][5][6][8].

Brand names: Paidakang
Other names: PEGylated exenatidepolyethylene glycol exenatide

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on visepegenatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on visepegenatide.

Explore the full profile